Compounds > 2-ethylhexyldiphenylphosphate
Page last updated: 2024-12-05

2-ethylhexyldiphenylphosphate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

2-Ethylhexyldiphenylphosphate (EHDPP) is a phosphate ester widely used as a plasticizer in polymers like polyvinyl chloride (PVC). It is synthesized through the reaction of diphenylphosphoryl chloride with 2-ethylhexanol. EHDPP is known for its excellent plasticizing properties, contributing to flexibility and durability in PVC materials. However, concerns regarding its potential environmental impact and health effects, including endocrine disruption, have led to research into its environmental fate and potential bioaccumulation. Studies on EHDPP focus on understanding its persistence, biodegradation, and potential risks to human health and the environment. The compound is often found in various consumer products, highlighting its importance in the manufacturing industry. Ongoing research aims to develop safer alternatives and optimize its use for sustainability.'
```

Cross-References

ID SourceID
PubMed CID14716
CHEMBL ID2105213
CHEBI ID188855
SCHEMBL ID93483
MeSH IDM0070164

Synonyms (61)

Synonym
unii-4f53z6ne1y
ec 214-987-2
4f53z6ne1y ,
(2-ethylhexyl)-difenylfosfat
di(2-ethylhexyl)phenylphosphate
4-06-00-00718 (beilstein handbook reference)
2-ethylhexyl diphenyl phosphate
octicizer
phosphoric acid, 2-ethylhexyl diphenyl ester
D05224
1241-94-7
octicizer (usan)
1-hexanol, 2-ethyl-, ester with diphenyl phosphate
einecs 214-987-2
santicizer 141
brn 2568983
hsdb 370
ccris 6199
(2-ethylhexyl)-difenylfosfat [czech]
octicizer [usan]
2-ethylhexyldiphenylphosphate
diphenyl 2-ethylhexyl phosphate
ethylhexyl diphenyl phosphate, 2-
diphenyl-2-ethylhexyl phosphate
2-ethylhexyl diphenylphosphate
ai3-16360
inchi=1/c20h27o4p/c1-3-5-12-18(4-2)17-22-25(21,23-19-13-8-6-9-14-19)24-20-15-10-7-11-16-20/h6-11,13-16,18h,3-5,12,17h2,1-2h3
cgslybdcegbzcg-uhfffaoysa-
P1021
phosphoric acid octyl diphenyl ester
phosphoric acid diphenyl 2-ethylhexyl ester
phosphoric acid 2-ethylhexyl diphenyl ester
CHEBI:188855
A805209
cas-1241-94-7
tox21_303313
dtxsid1025300 ,
dtxcid105300
NCGC00257002-01
CHEMBL2105213
FT-0645669
AKOS015889797
octicizer [hsdb]
(+/-)-octicizer
SCHEMBL93483
phosphoric aciddiphenyl ethylhexyl ester
2-ethylhexyl diphenyl ester phosphoric acid
phosflex 362
2-ethylhexyl diphenyl ester of phosphoric acid
CGSLYBDCEGBZCG-UHFFFAOYSA-N
2-ethyl-1-hexanol ester with diphenyl phosphate
W-108410
ehdphp
mfcd00059949
2-ethylhexyl diphenyl phosphate, pestanal(r), analytical standard
D78379
2-ethylhexyl diphenyl phosphate (technical)
2-ethylhexyl diphenyl phosphate (technical) 100 microg/ml in acetonitrile
AS-15838
2-ethylhexyl diphenyl phosphate (90per cent)
Q27259513
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
aryl phosphate
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (9)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
AR proteinHomo sapiens (human)Potency54.48270.000221.22318,912.5098AID1259243
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency27.30600.001022.650876.6163AID1224839
progesterone receptorHomo sapiens (human)Potency34.37620.000417.946075.1148AID1346795
retinoid X nuclear receptor alphaHomo sapiens (human)Potency23.61730.000817.505159.3239AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency49.62730.001530.607315,848.9004AID1224848; AID1224849; AID1259403
pregnane X nuclear receptorHomo sapiens (human)Potency7.69590.005428.02631,258.9301AID1346982
thyroid stimulating hormone receptorHomo sapiens (human)Potency27.30600.001628.015177.1139AID1224843; AID1224895
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency24.54120.057821.109761.2679AID1159528
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency57.80670.000323.4451159.6830AID743065; AID743067
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (37.50)18.7374
1990's0 (0.00)18.2507
2000's1 (12.50)29.6817
2010's3 (37.50)24.3611
2020's1 (12.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.67

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.67 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.97 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.67)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
triphenyl phosphate
triphenyl phosphate: structure. triphenyl phosphate : An aryl phosphate resulting from the formal condensation of phosphoric acid with 3 mol eq. of phenol.		2.5820aryl phosphateflame retardant;
plasticiser
docusate
Dioctyl Sulfosuccinic Acid: All-purpose surfactant, wetting agent, and solubilizer used in the drug, cosmetics, and food industries. It has also been used in laxatives and as cerumenolytics. It is usually administered as either the calcium, potassium, or sodium salt.		2.0210diester;
organosulfonic acid
ConditionIndicatedRelationship StrengthStudiesTrials
Delayed Effects, Prenatal Exposure
[description not available]		02.2510
Pregnancy
The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.		02.5920
Cancer of the Uterus
[description not available]		02.1510
Choriocarcinoma
A malignant metastatic form of trophoblastic tumors. Unlike the HYDATIDIFORM MOLE, choriocarcinoma contains no CHORIONIC VILLI but rather sheets of undifferentiated cytotrophoblasts and syncytiotrophoblasts (TROPHOBLASTS). It is characterized by the large amounts of CHORIONIC GONADOTROPIN produced. Tissue origins can be determined by DNA analyses: placental (fetal) origin or non-placental origin (CHORIOCARCINOMA, NON-GESTATIONAL).		02.1510
Uterine Neoplasms
Tumors or cancer of the UTERUS.		02.1510